Aptose Biosciences Files 8-K with Regulatory Updates
Ticker: APTOF · Form: 8-K · Filed: Dec 8, 2025 · CIK: 882361
Sentiment: neutral
Topics: 8-K, regulatory-disclosure, financials
Related Tickers: APTO
TL;DR
APTO filed an 8-K on Dec 8 for events on Dec 6, including Reg FD and financials. Check it out.
AI Summary
Aptose Biosciences Inc. filed an 8-K on December 8, 2025, reporting events as of December 6, 2025. The filing includes a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Lorus Therapeutics Inc., is incorporated in Canada and operates in the Biological Products sector.
Why It Matters
This 8-K filing provides important updates and disclosures from Aptose Biosciences Inc. to the SEC, which are crucial for investors to understand the company's current regulatory and financial standing.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting standard disclosures and financial statements, not indicating any immediate or significant adverse events.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former company name
- December 6, 2025 (date) — Earliest event reported date
- December 8, 2025 (date) — Filing date
FAQ
What specific events are being disclosed under Regulation FD?
The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in the provided text snippet.
What types of financial statements and exhibits are included in this filing?
The filing states that Financial Statements and Exhibits are included, but the specific content of these documents is not detailed in the provided text.
When was Aptose Biosciences Inc. formerly known as Lorus Therapeutics Inc.?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. with a date of name change on September 5, 2014.
What is the Standard Industrial Classification (SIC) code for Aptose Biosciences Inc.?
The SIC code for Aptose Biosciences Inc. is 2836, categorized under Biological Products (No Diagnostic Substances).
Where is Aptose Biosciences Inc. incorporated and what is its fiscal year end?
Aptose Biosciences Inc. is incorporated in Canada and its fiscal year ends on December 31.
Filing Stats: 500 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2025-12-08 07:15:26
Filing Documents
- f8k_120525.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 11KB
- 0001171843-25-007795.txt ( ) — 220KB
- gnw-20250101.xsd (EX-101.SCH) — 3KB
- gnw-20250101_def.xml (EX-101.DEF) — 25KB
- gnw-20250101_lab.xml (EX-101.LAB) — 35KB
- gnw-20250101_pre.xml (EX-101.PRE) — 24KB
- f8k_120525_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On December 6, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated December 6, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: December 6, 2025 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer